A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency

Trial Profile

A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs ACP 001 (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 05 Mar 2015 Results presented at Pediatric Endocrinology - Clinical Translational Session in March 2015, according to an Ascendis Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top